September 3, 2025 — Leads & Copy — Enveric Biosciences (NASDAQ: ENVB) today announced that Director and CEO, Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025, in New York City.
In the prerecorded presentation, Dr. Tucker will provide updates and discuss progress for the Company’s pipeline of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, including its lead candidate EB-003. Enveric designed EB-003 to deliver the therapeutic benefits of neuroplastogens while minimizing hallucinatory effects. EB-003 also offers a potential dual-targeting mechanism of action, with data demonstrating partial agonism at the 5-HT₂A receptor and agonism at the 5-HT₁B receptor.
During the conference, Dr. Tucker will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
For more information, please visit www.enveric.com.
Contact:
Name: Joseph Tucker, Ph.D.
Source: Enveric Biosciences
